# InMed Pharmaceuticals (NASDAQ: INM) Announces Three U.S. Patent Issuances

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates, today announced its receipt of three patents granted in the U.S., strengthening its patent portfolio. The issued patents include one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation. As of August 20, 2024, InMed has a total of 13 patent families covering new chemical entities, formulations, manufacturing processes and methods of use.

 “We are pleased to announce these U.S. patent issuances which help increase the commercial value of our programs and ensure the long-term protection of our drug research and development efforts. We are committed to continuing to build our patent portfolio to protect our novel drug candidates, methods of manufacturing these drugs, how they are formulated and how they are used to support the development of new treatments for diseases with high unmet medical needs,” said Eric A. Adams, InMed’s President and CEO.

 To view the full press release, visit https://cnw.fm/r84IM

 About InMed Pharmaceuticals Inc.

 InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. The company’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. Together with its subsidiary, BayMedica, InMed is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary small molecule drug candidates. For more information, visit www.InMedPharma.com.

 NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

 About CanadianCannabisWire

 CanadianCannabisWire (“CNW”) is a specialized communications platform with a focus on cannabis news and the Canadian cannabis sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled recognition and brand awareness. CNW is where breaking news, insightful content and actionable information converge.

 To receive SMS alerts from CanadianCannabisWire, text “CCWIRE” to 888-902-4192 (U.S. Mobile Phones Only)

 For more information, please visit https://www.CanadianCannabisWire.com

 Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: www.CanadianCannabisWire.com/Disclaimer

 CanadianCannabisWireToronto, ONwww.CanadianCannabisWire.com905.674.5977 OfficeEditor@CanadianCannabisWire.com

 CanadianCannabisWire is powered by IBN 

[Original/Source Press Release](https://rss.investorbrandnetwork.com/ibn-prem/inmed-pharmaceuticals-nasdaq-inm-announces-three-u-s-patent-issuances/) 

[Newsramp.com TLDR](https://newsramp.com/None) 